TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Net Cash Provided by (Used in) Investing Activities in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Net Cash Provided by (Used in) Investing Activities history and growth rate from Q1 2010 to Q3 2024.
  • Teva Pharmaceutical Industries Ltd Net Cash Provided by (Used in) Investing Activities for the quarter ending September 30, 2024 was $268M, a 45.7% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Net Cash Provided by (Used in) Investing Activities for the twelve months ending September 30, 2024 was $891M, a 6.58% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Net Cash Provided by (Used in) Investing Activities for 2023 was $968M, a 47.6% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Net Cash Provided by (Used in) Investing Activities for 2022 was $656M, a 56.9% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Net Cash Provided by (Used in) Investing Activities for 2021 was $1.52B, a 76.5% increase from 2020.
Net Cash Provided by (Used in) Investing Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Investing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $891M $268M +$84M +45.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $807M $178M -$124M -41.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $931M $144M -$37M -20.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $968M $301M +$132M +78.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 $836M $184M +$37M +25.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $799M $302M +$123M +68.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $676M $181M +$20M +12.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $656M $169M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 $147M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $179M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $161M -$347M -68.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 $508M +$256M +102% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q1 2020 $252M -$20M -7.35% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q1 2019 $272M -$767M -73.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $1.04B -$477M -31.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q1 2017 $1.52B +$3.93B Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q1 2016 -$2.42B -$2.2B -1004% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q1 2015 -$219M +$169M +43.6% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q1 2014 -$388M -$122M -45.9% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q1 2013 -$266M -$72M -37.1% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q1 2012 -$194M +$482M +71.3% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q1 2011 -$676M -$348M -106% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q1 2010 -$328M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.